Thermo Fisher: ‘Biopharma’s drive for efficiency plays into our sweet spot’

By Dan Stanton contact

- Last updated on GMT

Image: iStock/Jürgen François
Image: iStock/Jürgen François

Related tags: Thermo fisher, Vaccine

Increased biologics both on the market and in development and demand for greater manufacturing efficiencies have led to another strong quarter for Thermo Fisher.

For the second quarter 2016, Thermo Fisher announced sales across its divisions of $4.5bn (€4.1bn), up 6% on the same period last year.

“Growth in our bioproduction business was particularly strong,”​ said CEO Marc Casper, contributing to a 14% year-on-year growth to $1.3bn within the firm’s Life Science Solutions segment.

“We’re seeing strong demand from drugs getting on market, where [we see] volume really pick up,” ​he told investors during a conference call yesterday.

But Thermo Fisher is also benefitting from the growing number of drugs currently in the process development stage, he continued, while “vaccine production and the increase in vaccines is a big driver of demand.”

He added that currently the quality of the research by biopharma is turning a greater number of entities into clinical and commercialised products, which in turn is driving demand for Thermo Fisher’s own products.

“Even in what I think is very good end-markets, there is an efficiency driver amongst that customer base - whether it’s small biotech or large pharma - and that plays to our sweet spot for sure.

“We see it in the results across quarter in and quarter out, the very strong performance in the biopharma customer set for us. So, we feel very well-positioned in a good end-market.”

The quarter also mirrored a number of Thermo Fisher’s rival vendors​ in seeing growth on the back of demand for single-use technologies, an area Casper was confident would continue to drive sales going forward.

“There has been a very large shift from stainless steel to single-use, and that also accentuates the good growth in the market,”​ he said. “That’s been an excellent growth market for a number of years for us and one with a very bright future.”

Related news

Show more

Related products

show more

Featured eBook: Complex Protein Production

Featured eBook: Complex Protein Production

Catalent Pharma Solutions | 06-Mar-2018 | Technical / White Paper

Download the eBook written by Catalent experts to learn about innovative products and techniques for scale-up of complex biologics, get optimal cell culture...


Inline diafiltration enables continuous processing

Pall Life Sciences | 13-Feb-2018 | Application Note

The Cadence inline diafiltration (ILDF) device is designed for continuous processing, in-process buffer exchange or contaminant removal in various processes...

Think all buffer filters are the same?

Think all buffer filters are the same?

Pall Life Sciences | 01-Nov-2017 | Application Note

Pall’s Supor ® buffer filters are designed for high flow rates and rapid microbial removal. This can mean dramatic reductions in buffer handling costs...

Related suppliers